Overview of topics prescribing clinicians should discuss with patients when prescribing oral glucocorticoids.
Considerations . | Eligible Patients . | Timing . | Comments . |
---|---|---|---|
Risk for developing exogenous Cushing syndrome | All patients on long-term supraphysiologic glucocorticoid therapy | At the time of initiation | There are many sequelae of exogenous Cushing syndrome. Patients should be educated on the most common and clinically significant, including weight gain, sarcopenia, hyperglycemia, hypertension, bone demineralization. |
Risk for developing chronic adrenal insufficiency | Even transient adrenal insufficiency requires education to raise awareness for the need to stress dose when appropriate | ||
Education on stress dosing strategies | Patients on long-term supraphysiologic glucocorticoid therapy who have reduced dosing to physiologic, or subphysiologic, levels. | At least at the time when dosing approaches a physiologic range. | Dedicated education should be provided to prepare patients with confirmed, or likely, adrenal insufficiency for routine and emergent stress dosing. |
Education on injectable emergency glucocorticoid administration | |||
Glucocorticoid withdrawal syndrome | Patients on long-term supraphysiologic glucocorticoid therapy who are ready to begin tapering the dose. | At the time glucocorticoid tapering begins | Some patients on long term supraphysiologic glucocorticoid therapy experience symptoms as the doses are tapered. |
Considerations . | Eligible Patients . | Timing . | Comments . |
---|---|---|---|
Risk for developing exogenous Cushing syndrome | All patients on long-term supraphysiologic glucocorticoid therapy | At the time of initiation | There are many sequelae of exogenous Cushing syndrome. Patients should be educated on the most common and clinically significant, including weight gain, sarcopenia, hyperglycemia, hypertension, bone demineralization. |
Risk for developing chronic adrenal insufficiency | Even transient adrenal insufficiency requires education to raise awareness for the need to stress dose when appropriate | ||
Education on stress dosing strategies | Patients on long-term supraphysiologic glucocorticoid therapy who have reduced dosing to physiologic, or subphysiologic, levels. | At least at the time when dosing approaches a physiologic range. | Dedicated education should be provided to prepare patients with confirmed, or likely, adrenal insufficiency for routine and emergent stress dosing. |
Education on injectable emergency glucocorticoid administration | |||
Glucocorticoid withdrawal syndrome | Patients on long-term supraphysiologic glucocorticoid therapy who are ready to begin tapering the dose. | At the time glucocorticoid tapering begins | Some patients on long term supraphysiologic glucocorticoid therapy experience symptoms as the doses are tapered. |
Overview of topics prescribing clinicians should discuss with patients when prescribing oral glucocorticoids.
Considerations . | Eligible Patients . | Timing . | Comments . |
---|---|---|---|
Risk for developing exogenous Cushing syndrome | All patients on long-term supraphysiologic glucocorticoid therapy | At the time of initiation | There are many sequelae of exogenous Cushing syndrome. Patients should be educated on the most common and clinically significant, including weight gain, sarcopenia, hyperglycemia, hypertension, bone demineralization. |
Risk for developing chronic adrenal insufficiency | Even transient adrenal insufficiency requires education to raise awareness for the need to stress dose when appropriate | ||
Education on stress dosing strategies | Patients on long-term supraphysiologic glucocorticoid therapy who have reduced dosing to physiologic, or subphysiologic, levels. | At least at the time when dosing approaches a physiologic range. | Dedicated education should be provided to prepare patients with confirmed, or likely, adrenal insufficiency for routine and emergent stress dosing. |
Education on injectable emergency glucocorticoid administration | |||
Glucocorticoid withdrawal syndrome | Patients on long-term supraphysiologic glucocorticoid therapy who are ready to begin tapering the dose. | At the time glucocorticoid tapering begins | Some patients on long term supraphysiologic glucocorticoid therapy experience symptoms as the doses are tapered. |
Considerations . | Eligible Patients . | Timing . | Comments . |
---|---|---|---|
Risk for developing exogenous Cushing syndrome | All patients on long-term supraphysiologic glucocorticoid therapy | At the time of initiation | There are many sequelae of exogenous Cushing syndrome. Patients should be educated on the most common and clinically significant, including weight gain, sarcopenia, hyperglycemia, hypertension, bone demineralization. |
Risk for developing chronic adrenal insufficiency | Even transient adrenal insufficiency requires education to raise awareness for the need to stress dose when appropriate | ||
Education on stress dosing strategies | Patients on long-term supraphysiologic glucocorticoid therapy who have reduced dosing to physiologic, or subphysiologic, levels. | At least at the time when dosing approaches a physiologic range. | Dedicated education should be provided to prepare patients with confirmed, or likely, adrenal insufficiency for routine and emergent stress dosing. |
Education on injectable emergency glucocorticoid administration | |||
Glucocorticoid withdrawal syndrome | Patients on long-term supraphysiologic glucocorticoid therapy who are ready to begin tapering the dose. | At the time glucocorticoid tapering begins | Some patients on long term supraphysiologic glucocorticoid therapy experience symptoms as the doses are tapered. |
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.